Study directory

Depression studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
6115studies shown
Showing 1,789-1,800 of 6,115
Biological study icon
CompletedEUCTR 2017-000219-18

Psilocybin vs. escitalopram for major depressive disorder: comparative mechanisms

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
Why is this study shown?

This study is directly about Depression.

DepressionBiological
Countries
United Kingdom
Sponsor
Imperial College London
Condition
Depression
Drug study icon
CompletedEUCTR 2008-000506-36

Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose comparison study of escitalopram in combination with two fixed doses of gaboxadol to escitalopram in Major Depressive Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Depression.

DepressionDrugA study involving a medication or substance.
Countries
Austria
Sponsor
H. Lundbeck A/S
Condition
Depression
Drug study icon
CompletedEUCTR 2010-022397-14

Sequence Towards Recovery in Depression

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Finland
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
Finland
Sponsor
University of Helsinki - Erkki Isometsä
Condition
Depression
Drug study icon
Recruitment unclearEUCTR 2019-001621-27

A pilot study on oral s-ketamine for depression and demoralization in patients with advanced cancer receiving palliative care

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Netherlands
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
Netherlands
Sponsor
University Medical Center Groningen
Condition
Depression
Drug study icon
Recruitment unclearEUCTR 2022-000043-74

Defining and predicting neonatal inadaptation after gestational exposure to antidepressants: longitudinal exploratory analysis of psychoneuroendocrine risk factors and complications

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
Austria
Sponsor
Medical University of Vienna
Condition
Depression
Drug study icon
Recruitment unclearEUCTR 2009-010188-18

Effectiveness of Transmural Collaborative care and Duloxetine for major depressive disorder and (sub)chronic pain: a randomized placebo-controlled Multi-Centre trial.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Netherlands
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
Netherlands
Sponsor
Eli Lilly Nederland
Condition
Depression
Drug study icon
Recruitment unclearEUCTR 2008-005353-38

Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years, with Major depressive disord...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
France, United Kingdom, Bulgaria, ...
Sponsor
H. Lundbeck A/S
Condition
Depression
Drug study icon
Not recruitingEUCTR 2022-002757-26

A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) i...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

Multiple locations, including Burgas
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
Bulgaria, Estonia, Germany, ...
Sponsor
HMNC Holding GmbH
Condition
Depression
Drug study icon
Not recruitingEUCTR 2008-001581-91

A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
France, United Kingdom, Germany, ...
Sponsor
Takeda Global Research & Development Centre (Europe) Ltd.
Condition
Depression
Drug study icon
Not recruitingEUCTR 2014-000380-41

A Phase 3 Multicenter Study of the Long-term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepress...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
Bulgaria, Germany, Hungary, ...
Sponsor
Alkermes, Inc.
Condition
Depression
Drug study icon
Not recruitingEUCTR 2021-001172-41

An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
Bulgaria, Czechia, Finland, ...
Sponsor
Intra-Cellular Therapies, Inc.
Condition
Depression
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.